Learn how GLP‑1/GIP dual agonists like tirzepatide work at the molecular level to enhance insulin secretion, improve glucose control, and drive greater weight loss than GLP‑1 drugs alone. Explore mechanisms, incretin hormones, and key clinical trial results.
Learn how tirzepatide, a next‑generation “twincretin” peptide, combines dual GIP/GLP‑1 agonism, albumin binding, and DPP‑4 resistance to enable once‑weekly dosing, powerful glucose lowering, and surgery‑level weight loss in type 2 diabetes and obesity.